In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
410 News Items found
Pictured: American Association of Cancer Research Annual Meeting 2012
Announcement
Memorial Sloan Kettering Discoveries in Personalized Medicine Highlighted at Major Cancer Research Meeting; Investigators Honored

The American Association for Cancer Research (AACR), the world's oldest and largest professional organization dedicated to advancing cancer research, held its 2012 annual meeting in Chicago.
Dr. Elli Papaemmanuil in her lab
Why Clonal Hematopoiesis, a Blood Condition Related to Aging, Is Linked to Worse Outcomes for Cancer Patients

Researchers have shown how CH, a blood condition related to aging, affects cancer outcomes — through a phenomenon called tumor-infiltrating clonal hematopoiesis.
Dr. Rona Yaeger
FDA Approves First Colorectal Cancer Treatment that Targets G12C KRAS Gene

The targeted therapy adagrasib received accelerated approved for colorectal cancer caused by a mutation called KRAS-G12C, when used in combination with the drug cetuximab. MSK investigators have led much of the research that resulted in this combined drug approval.
Adrienne Boire at the lab bench
In the Lab
Inspired by a Patient, a Doctor Finds Answers for a Devastating Cancer Complication

Research is providing new clues about how cancer spreads to spinal fluid, a condition called leptomeningeal metastasis.
Colored x-ray of lung cancer
In the Lab
New Lung Cancer Therapy May Target Previously Untreatable Tumors

Researchers are developing uses for a drug that could benefit many people with lung cancer.
Bob Li, MD, PhD, MPH
First-Ever KRAS Inhibitor Gets Accelerated Approval for Non-Small Cell Lung Cancer

Memorial Sloan Kettering’s Bob Li served as principal investigator of the CodeBreaK 100 trial, the largest clinical trial conducted to date exclusively for patients with the KRAS G12C mutation.
Dr. Alicia Latham, Dr. Michael Walsh, Dr. Zsofia Stadler, and Megha Ranganathan
Feature
Inherited Cancer Risks: New Insights from MSK Presented at 2023 ASCO Meeting

MSK investigators are leading research focused on understanding how hereditary DNA mutations affect cancer development and therapy, and how to best treat people who carry these inherited risks in their genes.
Tumor mutation model
Finding
Tumor Mutational Burden Can Help Predict Response to Immunotherapy in Many Different Cancers

Investigators confirmed that people whose tumors have a high tumor mutational burden and were treated with immunotherapy lived longer.
MSK scientist Britta Weigelt and MSK physician-scientist Sarah Kim
New Progress Using Liquid Biopsies to Analyze cfDNA for Endometrial and Cervical Cancers

Learn how MSK’s liquid biopsy test, MSK-ACCESS, could improve the lives of patients with gynecologic cancers.
Illustration of cells with blue nuclei that have green DNA bits floating in the cytoplasm
In the Lab
Escape Artists: Cancer Cells Mimic Immune Cell Activity to Spread

Researchers have discovered that cancer cells may hijack an immune response to spread from a primary tumor to distant organs.